AngioDynamics News Releases http://investors.angiodynamics.com/ AngioDynamics News Releases en AngioDynamics Receives FDA Approval to Initiate Pilot Study for the Use of NanoKnife® to Treat Prostate Cancer http://investors.angiodynamics.com/news-releases/news-release-details/angiodynamics-receives-fda-approval-initiate-pilot-study-use LATHAM, N.Y. --(BUSINESS WIRE)--May 22, 2019-- AngioDynamics, Inc. (NASDAQ: ANGO), a leading provider of innovative, minimally invasive medical devices for vascular access, peripheral vascular disease, and oncology, today announced that the United States Food and Drug Administration ( FDA ) Wed, 22 May 2019 08:00:00 -0400 AngioDynamics News Releases 19536 AngioDynamics Announces First Patient Enrolled in NanoKnife® DIRECT Clinical Study for the Treatment of Stage III Pancreatic Cancer http://investors.angiodynamics.com/news-releases/news-release-details/angiodynamics-announces-first-patient-enrolled-nanoknifer-direct LATHAM, N.Y. --(BUSINESS WIRE)--May 13, 2019-- AngioDynamics, Inc. (NASDAQ: ANGO), a leading provider of innovative, minimally invasive medical devices for vascular access, peripheral vascular disease, and oncology, today announced enrollment of the first patient in its NanoKnife ® Irreversible Mon, 13 May 2019 08:00:00 -0400 AngioDynamics News Releases 19531 AngioDynamics Announces Agreement to Sell NAMIC® Fluid Management Business to Medline Industries, Inc. for $167.5 Million http://investors.angiodynamics.com/news-releases/news-release-details/angiodynamics-announces-agreement-sell-namicr-fluid-management AngioDynamics to host conference call today at 5:00 p.m. ET LATHAM, N.Y. --(BUSINESS WIRE)--Apr. 17, 2019-- AngioDynamics, Inc. (NASDAQ: ANGO), a leading provider of innovative, minimally invasive medical devices for oncology, vascular access, and peripheral vascular disease, today announced that Wed, 17 Apr 2019 16:05:00 -0400 AngioDynamics News Releases 19516 AngioDynamics’ DIRECT Clinical Study Receives Institutional Review Board Approval for the Treatment of Stage III Pancreatic Cancer http://investors.angiodynamics.com/news-releases/news-release-details/angiodynamics-direct-clinical-study-receives-institutional LATHAM, N.Y. --(BUSINESS WIRE)--Apr. 17, 2019-- AngioDynamics, Inc. (NASDAQ:ANGO), a leading provider of innovative, minimally invasive medical devices for vascular access, peripheral vascular disease, and oncology, today announced that the Company received central Institutional Review Board (IRB) Wed, 17 Apr 2019 08:01:00 -0400 AngioDynamics News Releases 19506 AngioDynamics Reports Fiscal 2019 Third Quarter Financial Results http://investors.angiodynamics.com/news-releases/news-release-details/angiodynamics-reports-fiscal-2019-third-quarter-financial Fiscal 2019 Third Quarter Highlights Net sales of $86.3 million , an increase of 3.0% year over year Gross margin declined 10 basis points year over year to 54.1% GAAP EPS of $0.02 per share; adjusted EPS of $0.19 per share Cash provided by operations of $8.3 million ; capital expenditures of $0.9 Tue, 02 Apr 2019 07:00:00 -0400 AngioDynamics News Releases 19471 AngioDynamics to Present at the Needham Healthcare Conference http://investors.angiodynamics.com/news-releases/news-release-details/angiodynamics-present-needham-healthcare-conference LATHAM, N.Y. --(BUSINESS WIRE)--Apr. 1, 2019-- AngioDynamics, Inc.  (NASDAQ: ANGO), a leading provider of innovative, minimally invasive medical devices for vascular access, peripheral vascular disease, and oncology, today announced that Michael C. Greiner , Executive Vice President and Chief Mon, 01 Apr 2019 16:01:00 -0400 AngioDynamics News Releases 19456 AngioDynamics Receives FDA Approval to Initiate NanoKnife® DIRECT Clinical Study for the Treatment of Stage III Pancreatic Cancer http://investors.angiodynamics.com/news-releases/news-release-details/angiodynamics-receives-fda-approval-initiate-nanoknifer-direct LATHAM, N.Y. --(BUSINESS WIRE)--Apr. 1, 2019-- AngioDynamics, Inc. (NASDAQ:ANGO), a leading provider of innovative, minimally invasive medical devices for vascular access, peripheral vascular disease and oncology, today announced that the United States Food and Drug Administration ( FDA ) approved Mon, 01 Apr 2019 06:00:00 -0400 AngioDynamics News Releases 19451 CORRECTING and REPLACING OARtrac® Radiation Dose Monitoring System Receives Expanded FDA Clearance for Electron Radiation Therapy http://investors.angiodynamics.com/news-releases/news-release-details/correcting-and-replacing-oartracr-radiation-dose-monitoring LATHAM, N.Y. --(BUSINESS WIRE)--Mar. 28, 2019-- Second paragraph, first sentence of release should read: The additional indications clear the OARtrac System for use with patient-specific, pre-calibrated Plastic Scintillating Detector (PSD) sensors used during cancer treatments to measure photon and Thu, 28 Mar 2019 16:01:00 -0400 AngioDynamics News Releases 19446 AngioDynamics to Report Fiscal 2019 Third Quarter Financial Results on April 2, 2019 http://investors.angiodynamics.com/news-releases/news-release-details/angiodynamics-report-fiscal-2019-third-quarter-financial-results LATHAM, N.Y. --(BUSINESS WIRE)--Mar. 12, 2019-- AngioDynamics, Inc.  (NASDAQ: ANGO), a leading provider of innovative, minimally invasive medical devices for vascular access, peripheral vascular disease, and oncology, today announced that it will report financial results for the third quarter of Tue, 12 Mar 2019 16:01:00 -0400 AngioDynamics News Releases 19436 AngioDynamics Wins Patent Infringement Dispute With Bard http://investors.angiodynamics.com/news-releases/news-release-details/angiodynamics-wins-patent-infringement-dispute-bard LATHAM, N.Y. --(BUSINESS WIRE)--Mar. 8, 2019-- AngioDynamics, Inc. (NASDAQ: ANGO), a leading provider of innovative, minimally invasive medical devices for vascular access, peripheral vascular disease and oncology, today announced that the United States District Court for the District of Delaware , Fri, 08 Mar 2019 13:01:00 -0500 AngioDynamics News Releases 19421